Promising drug remibrutinib offered Long-Term to patients in need

NCT ID NCT07456891

Recruiting now Disease control Sponsor: Novartis Pharmaceuticals Source: ClinicalTrials.gov ↗

First seen Mar 10, 2026 · Last updated May 21, 2026 · Updated 12 times

Summary

This study offers continued treatment with remibrutinib to people who have already completed a Novartis-sponsored study of the drug and are benefiting from it. Up to 212 participants will receive the treatment for up to three years while researchers monitor long-term safety. The goal is to provide access to those who cannot get remibrutinib outside a clinical trial.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for INDICATION OF THE PARENT PROTOCOL are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Contacts and locations

Show contact details

Study contacts

Contact

Phone: •••-•••-•••• Email: •••••@•••••
Contact

Locations

Novartis Investigative Site
RECRUITING

London, Ontario, N6H 5L5, Canada
Novartis Investigative Site
RECRUITING

Daegu, Dalseo Gu, 42602, South Korea
Novartis Investigative Site
RECRUITING

Gwangju, 61469, South Korea
Novartis Investigative Site
RECRUITING

Seoul, 03080, South Korea

Conditions

Explore the condition pages connected to this study.

INDICATION OF THE PARENT PROTOCOL